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Abstract
Objectives To assess the clinical and the economic impacts of
intraprocedural use of contrast-enhanced ultrasound (CEUS)
in patients undergoing percutaneous radiofrequency ablation
for small (<2.5 cm) hepatocellular carcinomas.
Methods One hundred and forty-eight hepatocellular carcino-
mas in 93 patients were treated by percutaneous radiofrequen-
cy ablation and immediate assessment by intraprocedural
CEUS. Clinical impact, cost effectiveness, and budget,
organisational and equity impacts were evaluated and com-
pared with standard treatment without intraprocedural CEUS
using the health technology assessment approach.
Results Intraprocedural CEUS detected incomplete ablation
in 34/93 (36.5 %) patients, who underwent additional treat-
ment during the same session. At 24-h, complete ablation was
found in 88/93 (94.6 %) patients. Thus, a second session of
treatment was spared in 29/93 (31.1 %) patients. Cost-
effectiveness analysis revealed an advantage for the use of
intraprocedural CEUS in comparison with standard treatment
(4,639 vs 6,592) with a 21.9 % reduction of the costs to treat
the whole sample. Cost per patient for complete treatment was
€ 4,609 versus € 5,872 respectively. The introduction of
intraprocedural CEUS resulted in a low organisational impact,
and in a positive impact on equity
Conclusions Intraprocedural use of CEUS has a relevant clin-
ical impact, reducing the number of re-treatments and the
related costs per patient.
Teaching Points
• CEUS allows to immediately asses the result of ablation.
• Intraprocedural CEUS decreases the number of second
ablative sessions.
• Intraprocedural CEUS may reduce cost per patient for com-
plete treatment.
• Use of intraprocedural CEUS may reduce hospital budget.
• Its introduction has low organisational impact, and relevant
impact on equity.
Keywords Radiofrequency ablation . Hepatocellular
carcinoma . Cost-effectiveness . Clinical impact . Budget
impact . Health technology assessment . Intraprocedural
contrast-enhanced ultrasound
Introduction
Radiofrequency ablation (RFA) is widely accepted as a treat-
ment for small hepatocellular carcinomas (HCC), with effica-
cy comparable to surgical resection for these lesions [1–6].
However, complete coagulation necrosis of the index tumour
with a sufficient ablative margin is necessary before an RFA
treatment can be considered complete [7, 8]. If only partial
necrosis is achieved, future re-treatment may be necessary,
which may result in increased patient discomfort, greater
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technical difficulties, higher failure rates and an increased
possibility of complications.
Lesion targeting and intraprocedural monitoring are gener-
ally performed using non-contrast-enhanced imaging, includ-
ing ultrasound (US), computed tomography (CT) and mag-
netic resonance imaging (MRI). On the other hand, precise
assessment of technical success requires the use of contrast-
enhanced imaging, and is generally performed using contrast-
enhanced CT (CE-CT) and/or contrast-enhanced MRI (CE-
MRI) within 1 week after the procedure [4, 9–12]. The use of
contrast-enhanced US (CEUS) to assess the results of liver
RFA has been described, and a diagnostic accuracy similar to
CE-CT has been reported [13–18]. For this reason CEUS
immediately after ablation has been proposed as an appropri-
ate technique to identify possible incomplete ablation and the
need for re-treatment within the same operative session [18,
19]. This approach could theoretically reduce the number of
re-treatments required subsequently, with a potentially signif-
icant impact on both costs and patient outcomes.
At our institution, CEUS is always performed
intraprocedurally immediately following ablation procedures
and, when incomplete ablation is depicted, CEUS-guided
targeted re-treatment is performed during the same treatment
session. The aim of this study was to assess both the clinical
and economic impact of intraprocedural CEUS in patients
undergoing percutaneous RFA for HCC.
Materials and methods
Patients
A retrospective review was performed of consecutive patients
that had undergone percutaneous thermal ablation of liver
tumours at our institution between January 2008 and June
2011. Approval was obtained by the Institutional Review
Board and patient consent was waived.
All patients with HCC lesions smaller than 2.5 cm in size
treated by RFA were included in the analysis. At our institu-
tion, in all the patients with HCC smaller than 2.5 cm treat-
ment is planned with a single insertion of the electrode.
Patients were excluded if they had undergone treatment for
metastatic tumours or had undergone prior treatment by mi-
crowave ablation. In addition, patients were excluded if their
tumours were undetectable by US or if their tumours were
larger than 2.5 cm.
Procedure
Radiofrequency ablation with US guidance was performed
under general anaesthesia, using a 3.5-MHz probe with an
incorporated guide and a 17-gauge cooled-tip electrode (Cool-
Tip; Valleylab, Burlington, MA) with a 3-cm exposed portion.
All procedures were performed by two of three interventional
radiologists with more than 10 years’ experience in percutane-
ous thermal ablations and use of CEUS in the diagnostic and
interventional field. CEUS was performed using 2.4 ml sul-
phur hexafluoride microbubbles (SonoVue, Bracco, Italy) be-
fore and immediately after each RFA procedure to monitor and
assess the therapeutic result before terminating the treatment
session. For all examinations, contrast-specific software (Co-
herent Contrast Imaging [CCI] and Contrast Pulse Sequencing
[CPS], Siemens Acuson, USA; ECI, Siemens, Germany; Con-
trast Tuned Imaging [CnTI], Esaote, Italy) in continuous mode
with very low mechanical index (0.01-0.1) was employed.
Pre-treatment CEUS was performed as an initial step in the
RFA session in order to reproduce lesion mapping on CE-CT
and CE-MRI, and to allow real-time lesion targeting. Images
and/or movie clips were digitally stored to be compared with
the immediate post-ablation study. Immediate post-ablation
evaluation using CEUS was performed 5–10 min after the
assumed completion of the RFA session, with the patient still
under general anaesthesia.
If residual enhancement was found in the ablated mass and/
or the volume of the devascularised area was considered too
small to cover the entire tumour with a sufficiently thick safety
margin, the treatment was considered incomplete and a new
ablation was performed immediately during the same treat-
ment session, as previously described [19]. CEUS was per-
formed again after the new ablation to confirm the complete-
ness of the treatment. CE-CT or CE-MRI was performed at
24 h in all cases and was used as the reference standard for
assessment of technical success.
A case with positive findings of intraoperative CEUS that
modified the treatment is shown in Fig. 1
Clinical impact
The number of patients in whom intraprocedural CEUS re-
vealed incomplete treatment at the end of the ablation and who
underwent a second CEUS-guided ablation in the same inter-
ventional session was retrospectively evaluated on the basis of
the description of the procedure recorded in the operative
registry. The number of incompletely treated lesions was
determined by the 24-h post-ablation CE-CTor CE-MRI, read
by the same three radiologists with more than ten years’
experience. Patients in whom CEUS revealed incomplete
ablation and who underwent a second CEUS-guided ablation
in the same session with complete necrosis at 24-h follow-up
were considered to have avoided a second intervention as a
result of the intraprocedural use of CEUS.
Health technology assessment
The economic and managerial analysis was conducted using a
health technology assessment approach, based on the
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Fig. 1 The case of a single HCC
that had undergone RFA and
immediate re-treatment because
of the detection of residual
unablated tumour with
intraprocedural CEUS. In the left
hepatic lobe pre-treatment CE-CT
(a) and CEUS (b) show an HCC
with typical hypervascularity in
arterial phase (arrowheads). c
The HCC is treated with single
insertion of RF electrode
(arrowheads). d Gas produced by
heating during ablation
(arrowheads) seems to diffuse
beyond the tumour margins. e
Intraprocedural CEUS performed
few minutes after electrode
withdrawal demonstrates residual
enhancing viable tumour (arrows)
at the periphery of the volume of
necrosis (arrowheads). f Second
insertion of RF electrode is
performed aiming at the area of
residual enhancement (arrows)
(dotted linepath of the electrode).
g Post-ablation CEUS
demonstrates large volume of
necrosis (arrowheads) with
complete ablation of the residual
tumour previously detected
(arrows). h Twenty-four-hour
post-ablation CE-CT confirms
that treatment is complete
(arrowheadsablated zone)
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Guidelines for the Economic Evaluation of Health Technolo-
gies [20]. A cost-effectiveness analysis was conducted, along
with a budget impact analysis, and analyses of the impacts on
the organisation and on equity. The effectiveness parameter
taken into account for the cost-effectiveness analysis was the
percentage of patients who avoided a second session of treat-
ment due to incomplete ablation.
The costs associated with the procedures were collected
with a bottom-up approach, using Activity Based Costing
[21–23]. Each procedure was divided into single phases and
the related costs of each phase were evaluated, considering
direct and indirect costs referring to human resources, ma-
chines (8-year amortisation), surgical instruments, consump-
tion materials, drugs and overheads. All phases, from pre-
admission to patient discharge for a standard patient without
complications, were evaluated using retrospective data related
to the study sample in terms of time needed for percutaneous
ablation, considering the number of lesions and length of
hospitalisation. To assess procedure-related costs without
intraprocedural CEUS, a differential analysis was performed,
removing time and resources necessary to perform CEUS.
The perspective taken into consideration was that of the
hospital. Cost data, provided by the management control service
of the hospital, are value added tax inclusive and refer to 2011.
A sensitivity analysis was conducted to test the robustness
of the results. One thousand simulations were performed,
varying each cost category and effectiveness data with uni-
form distributions as follows: human resources ±10 %; ma-
chinery 0, +750 % (most of the technologies used for the
intervention analysed completed the amortisation period,
therefore a high range for sensitivity analysis was considered);
laboratory exams ±5 %; consumables ±10 %; drugs ±5 %;
hotel services ±5 %; overheads 0, -5 %; effectiveness ±5 %.
Cost variations were the same for the two procedures in each
simulation, while effectiveness could have different values in
the same simulation.
The impact on the hospital budget was calculated consid-
ering the annual number of RFA procedures for HCC per-
formed in 2010. Two scenarios were than taken into
consideration:
– Assessment of the impact of the use of CEUS, using the
real number of interventions and reinterventions due to
incomplete ablations within the period.
– Assessment of the impact of the procedure without
intraprocedural CEUS, considering the treatments and
the hypothetical number of re-treatments resulting from
incomplete ablations.
The costs of each ablation and re-treatment were calculated
for both procedures, along with the diagnosis-related group
(DRG) reimbursement provided by the Regional Healthcare
Service of Lombardy Region.
A sensitivity analysis was performed using bootstrapping
methodology to simulate 100 different samples, considering a
uniform distribution of ±10 % in the number of patients with
one and two lesions.
The impact on the organisation was assessed through guid-
ed interviews with three experienced radiologists of the Inter-
ventional Oncologic Department of the hospital. It allowed
quantification of the economic impact of the use of
intraprocedural CEUS on the organisation and the perception
of the short-term and medium/long-term organisational im-
pact, using a seven-point scale (from highly negative to highly
positive), compared with ablations without intraprocedural
CEUS. The parameters taken into consideration were related
to human resources, space needed, software or hardware
needs, etc.
The impact on equity was investigated through guided
interviews with the three experienced radiologists, detecting
their perception using a seven-point scale concerning the two
different processes in terms of adverse events, patient safety,
accessibility, waiting lists, usability and invasiveness.
Results
During the course of the study, 384 patients underwent per-
cutaneous RFA for 640 liver lesions. Of these, 148 HCC
lesions in 93 patients met the inclusion criteria and entered
our analysis. Among the 93 patients, 59 (63.4 %) were men
and 34 (36.6 %) women, with an age range of 72.3±7.9 years
(median, 73.5 years). Treated HCC lesions had a maximum
diameter of 1.86±0.57 cm (median, 2.0 cm). A single HCC
was treated in 58 (62.4 %) patients, while two, three and four
HCC lesions were treated in 23 (24.7 %), 8 (8.6 %) and 4
(4.3 %) patients, respectively.
Clinical impact
Intraprocedural CEUS detected incomplete treatment after the
first ablation in 43/148 (29.0 %) lesions in 34/93 (36.5 %)
patients. All 34 patients underwent additional treatment dur-
ing the same session until complete absence of vascularisation
was demonstrated by intraprocedural CEUS. At 24-h CE-CT
or CE-MRI, complete ablation was found in 143/148 (96.6 %)
lesions in 88/93 (94.6 %) patients. Only 5/93 (5.4 %) patients
subsequently underwent local re-treatment. Thus, as a result of
intraprocedural CEUS, a second session of treatment was
spared in 29/93 (31.1 %) patients.
Health technology assessment
The results of the cost-effectiveness analysis are reported in
Table 1. The mean cost of RFAwithout intraprocedural CEUS
was € 4,228, which was 3.7 % less than RFA with
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intraprocedural CEUS. This difference was due to the longer
time length of the RFA procedure and to the additional use of
contrast agent.
Considering the effectiveness of RFA with and without
intraprocedural CEUS in terms of avoided reinterventions,
the use of intraprocedural CEUS led to a 94.57 % value versus
64.13 % (30.43 % less) when CEUS was not employed. The
cost-effectiveness assessment revealed a significant advantage
to the use of intraprocedural CEUS (4,639 vs 6,592) (Fig. 2).
Though more expensive, the procedure with intraprocedural
CEUS proved to be more effective, with an incremental cost-
effectiveness ratio (ICER) (that represents the cost per effec-
tiveness point gained) of 521.97 per intervention. The sensi-
tivity analysis results referred to the ICER are reported in
Fig. 3. The probability of intraprocedural CEUS being cost-
effective was over 50 %, with a willingness to pay a threshold
of € 575. This represents the willingness to pay of the Health
Service to reach a 1-point effectiveness gain.
The budget impact analysis demonstrated that the use of
intraprocedural CEUS allowed a reduction in terms of cost of
21.95 % compared with treatment without intraprocedural
CEUS, due to avoided re-treatments. A 25.95 % reduction in
terms of reimbursement was also observed, since the number
of re-treatments in the sample considered is higher without
intraprocedural CEUS and, therefore, the considered treat-
ments and DRGs are higher in this scenario. The mean cost
per patient for complete treatment (including first and second
RFA) was € 4,609 with the use of intraprocedural CEUS
versus € 5,872 for the standard procedure.
The sensitivity analysis revealed minimum and maximum
cost reductions for the hospital of 19.02 % and 23.26 %,
respectively, with the use of intraprocedural CEUS.
The analysis of the organisational impact led to the identi-
fication of hypothetic investments necessary for the introduc-
tion of CEUS within an interventional radiology department
of less than € 11,000. Investments were considered to mainly
involve software update, training of radiologists and meetings.
The perceived short-term organisational impact results are
reported in Fig. 4. In the short term, the introduction of CEUS
leads to a medium negative impact on learning time, a low
negative impact on training for personnel directly involved in
the procedure, and for support personnel, meetings within the
department (leading to an hypothetical loss of productivity for
Table 1 Cost-Effectiveness Analysis Results
Procedure Mean cost (€) Effectiveness Δ cost (€) Δ effectiveness Cost effectiveness
Without intraprocedural CEUS 4,228 64.13 % 4,228 64.13 % 6,592
With intraprocedural CEUS 4,387 94.57 % + 159 + 30.43 % 4,639
Themean cost per procedure is lower without the use of intraprocedural CEUS, while the effectiveness value has a substantial increase with the use of the
aforementioned diagnostic procedure. The cost effectiveness value shows a lower, and then favourable, value for the procedure with the use of
intraprocedural CEUS
Fig. 2 Incremental cost-effectiveness plan. The plan shows the incre-
mental cost and effectiveness of the procedure with intraoperational
CEUS, compared with the standard procedure. There is an increase in
effectiveness and in costs, the procedure being located in the North-East
quadrant. The acceptability of the use of the procedure depends on the
willingness to pay of the payer
Fig. 3 Incremental cost-effectiveness ratio (ICER) sensitivity analysis
results. The figure shows the percentage of the 1,000 ICERs calculated
with the sensitivity analysis performed, which are cost effective (com-
pared with the other procedure), considering hypothetical willingness to
pay values for the regional healthcare service to increase the effectiveness
of 1 unit. The cost effectiveness acceptability curve shows a probability
higher than 50% for the procedure with intraprocedural CEUS to be cost-
effective, with a willingness to pay per additional effectiveness unit of
€ 575
Insights Imaging (2014) 5:209–216 213
all the staff involved) and software update. A positive medium
impact was determined for internal processes and appropriate-
ness of requests for diagnostic exams, both leading to a
reduction in terms of further interventions or investigations
needed for the same patient. Considering a medium/long-term
perspective, the positive impacts remain while the negative
impacts do not further affect the organisation.
Considering the impact on equity, the use of
intraprocedural CEUS was associated with a highly positive
impact for the quality of data related to the investigated
diagnostic question, which leads to more precise information
to support medical decisions, a medium positive impact on
reductions in waiting lists for surgical interventions, avoiding
re-treatments, and a low negative impact on usability and
invasiveness of the procedure.
Discussion
Our results show that the intraprocedural use of CEUS can
reduce the number of incomplete treatments and consequently
the number of re-treatments, as well as the total costs of RFA
for HCC. RFA has been shown to be effective in the treatment
of small HCC lesions, with results comparable to surgical
resection [1–6]. However, given that the assessment of the
completeness of ablation is generally performed after the
treatment, often more than one ablation session is required
to achieve complete response [9, 10], with increasing risk of
complications for the patient and increasing costs. In our
series we achieved complete ablation of 96.6 % of lesions in
94.6 % of patients at 24 h, which is comparable with results
reported in the literature [1–5].
CEUS can be performed in the operating room after the
ablation, and has been used in different fields for the immedi-
ate assessment of completeness of ablation [19, 24]. Particu-
larly, CEUS has been proven to be as accurate as other
contrast-enhanced imaging modalities for the assessment of
technical success after RFA [13–18]. For this reason some
authors recommend CEUS immediately after RFA to permit
re-treatment during the same interventional session if incom-
plete ablation is detected [17–19]. We adopted this strategy at
our institution and, by using CEUS immediately after RFA,
were able to detect incomplete ablation in 29.0 % of lesions in
36.5 % of patients. In these patients we were able to perform
an immediate CEUS-guided targeted re-treatment that led to
complete ablation in 94.6 % of patients based on 24-h follow-
up. Thus, a second session of treatment was avoided in 31.1%
of patients. The need of a second intervention—that we per-
formed in the same session—in our group is slightly higher
than other series reported in the literature [1–9]. Several
factors may have contributed to this result. Firstly, being a
second-level centre, with high expertise in the treatment of
liver diseases, patients are often referred to our department
from other hospitals. Thus, our group included a high propor-
tion of “complex cases” compared with cases at more general
interventional radiology departments, with an increased mean
technical difficulty of cases to be treated. Moreover, 37.6 % of
patients in our series were treated for more than one tumour in
the same session. Third, the result of CEUS was judged by the
interventional radiologist performing the treatment, and
equivocal cases were generally considered as incompletely
ablated, and underwent a second ablative treatment. Thus,
the rate of incomplete treatment after the first ablation may
have been slightly overestimated. Moreover, we finally
Fig. 4 Perceived short-term
organisational impact. The use of
intraprocedural CEUS leads to a
short-term medium negative
impact on learning time, and a
low negative impact on training
for personnel directly involved in
the procedure, support personnel,
meetings within the department
and software update. It leads to a
positive medium impact on the
internal processes of the ward and
appropriateness of requests for
diagnostic exams, leading to a
reduction in terms of further
interventions or investigations
needed for the same patient
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achieved complete ablation at 24 hours in 94.6 % of
patients.
From an economic point of view, compared with the stan-
dard procedure, the introduction of intraprocedural CEUS
resulted in a 3.7% increase in costs, due to a longer procedural
time and the cost of the contrast agent. However, the use of
intraprocedural CEUS resulted in better cost-effectiveness
compared with the standard procedure and a higher probabil-
ity of being cost-effective, with a € 575 threshold of willing-
ness to pay.
From a hospital perspective, the intraprocedural use of
CEUS resulted in a 21.95 % reduction in costs due to a lower
number of re-treatments. This would result in the possibility of
performing ablations on a greater number of patients, with
consequently more effective use of resources and shortening
of waiting lists. From the point of view of the Health Service,
the use of intraprocedural CEUS allows a lower cost per
patient for complete treatment, resulting in savings for the
entire service.
The introduction of intraprocedural CEUS in centres where
CEUS is already employed for other purposes would result in
a low organisational impact, but to a relevant impact on equity,
since the avoided re-treatments would have a positive impact
on the quality-of-life of patients, decreasing their stress levels
and reducing the number of hospitalisations.
Even though CEUS has a diagnostic accuracy similar to
CE-CT in the assessment of treatment results [13–18], there
are only few studies that compare CEUS with other contrast-
enhanced modalities immediately after RFA. A second possi-
ble limitation of our study is that being a second-level centre,
with a larger number of “complex cases” compared with more
general interventional radiology departments, the same anal-
ysis performed in a different hospital might lead to different
results. Moreover, the decision to perform a new ablation
immediately, in the same session, was made on the basis of
the critical analysis of the result of intraprocedural CEUS
made by the interventional radiologists. In some cases with
an easy path to the target and a safely located tumour, even
with equivocal result of incomplete ablation at CEUS a second
ablation was performed. Thus, the need for immediate re-
treatment and, consequently, the clinical and economic im-
pacts of CEUS, could have been overestimated in our series.
As a consequence, unnecessary repetition of treatment in a
significant number of patients would have happened. A fourth
limitation is the absence of a true control group in which
CEUS was not performed, as our results were obtained by
comparing a real group in which CEUS was performed with a
hypothetical one in which CEUS was not performed. A fur-
ther bias in our study derives from the inclusion of only small
(<2.5 cm) HCCs in our series.
In conclusion, the intraprocedural use of CEUSmay have a
relevant clinical impact in reducing the number of second
ablative sessions needed to achieve a complete ablation of
the tumour to be treated. Moreover, the intraprocedural use of
CEUSmay significantly reduce the costs per patient related to
the percutaneous treatment with RFA of patients with HCC,
being also characterised by a low organisational impact, and in
a relevant impact on equity
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